ZIC2 and lip and oral cavity carcinoma: With respect to the two compounds that were predicted to present higher affinity to oral cancer patients with higher ZIC2 expression, AZD8186 is a selective phosphoinositide 3-kinase/AKT/mTOR inhibitors that demonstrated antitumor potency in various PTEN-deficient tumors [27]; there is no documented pharmacological effect of ERK_2440 in human cancers.